- Trials with a EudraCT protocol (3,049)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
3,049 result(s) found for: Age of onset.
Displaying page 1 of 153.
EudraCT Number: 2009-012201-19 | Sponsor Protocol Number: EX2211-3748 | Start Date*: 2010-08-24 | |||||||||||
Sponsor Name:Novo Nordisk A/S | |||||||||||||
Full Title: LEADER Liraglutide Effect and Action in Diabetes: Evaluation of cardiovascular outcome Results A Long-term, Multi-centre, International, Randomised Double-blind, Placebo-controlled Trial to Determi... | |||||||||||||
Medical condition: Type 2 diabetes mellitus | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Completed) IE (Completed) SE (Completed) DE (Completed) NL (Completed) FI (Completed) AT (Completed) GB (Completed) CZ (Completed) BE (Completed) DK (Completed) PL (Completed) GR (Completed) ES (Completed) IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2011-001752-10 | Sponsor Protocol Number: TAK-875_302 | Start Date*: 2012-10-30 | |||||||||||||||||||||||||||||||
Sponsor Name:Takeda Global Research & Development Centre (Europe) Ltd. | |||||||||||||||||||||||||||||||||
Full Title: A Multicenter, Randomized, Double-Blind, Placebo- and Active-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of TAK-875 25 mg and 50 mg Compared to Placebo and Sitagliptin 100 mg When... | |||||||||||||||||||||||||||||||||
Medical condition: Type 2 diabetes mellitus (T2DM) | |||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||||||||||||
Trial protocol: HU (Prematurely Ended) CZ (Prematurely Ended) SK (Prematurely Ended) BG (Prematurely Ended) IT (Prematurely Ended) | |||||||||||||||||||||||||||||||||
Trial results: View results |
EudraCT Number: 2010-021057-39 | Sponsor Protocol Number: NN2211-1800 | Start Date*: 2010-11-11 | |||||||||||
Sponsor Name:Novo Nordisk A/S | |||||||||||||
Full Title: A Randomized, Double-blind, Placebo Controlled Trial to Assess Safety/Tolerability, Pharmacokinetics & Pharmacodynamics of Liraglutide in Paediatric (10 – 17 years old) Subjects with Type 2 Diabetes | |||||||||||||
Medical condition: Type 2 Diabetes | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) SI (Completed) BE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2011-002741-35 | Sponsor Protocol Number: TAK-875_301 | Start Date*: 2012-02-15 | ||||||||||||||||||||||||||
Sponsor Name:Takeda Global Research & Development Centre (Europe) Ltd. | ||||||||||||||||||||||||||||
Full Title: A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Daily Oral TAK-875 25 mg and 50 mg Compared with Placebo in Subjects with Type 2 Diabetes | ||||||||||||||||||||||||||||
Medical condition: Type 2 diabetes mellitus (T2DM) | ||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||||||||||||
Trial protocol: SK (Completed) HU (Completed) BG (Completed) | ||||||||||||||||||||||||||||
Trial results: View results |
EudraCT Number: 2009-015255-25 | Sponsor Protocol Number: 1218.63 | Start Date*: 2010-03-03 | |||||||||||
Sponsor Name:Boehringer Ingelheim bv | |||||||||||||
Full Title: A phase III randomised, double-blind, placebo-controlled, parallel group, efficacy and safety study of linagliptin (5 mg), administered orally once daily over 24 weeks in type 2 diabetic patients (... | |||||||||||||
Medical condition: Patients with type 2 diabetes. | |||||||||||||
|
|||||||||||||
Population Age: Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: NL (Completed) DK (Completed) SE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2004-004528-11 | Sponsor Protocol Number: BM18102 | Start Date*: 2005-04-15 | |||||||||||
Sponsor Name:F. Hoffmann-La Roche Ltd | |||||||||||||
Full Title: Multicenter, double-blind, randomized, placebo-controlled, dose ranging phase 2 study to investigate efficacy, safety, tolerability and pharmacokinetics of the DPPIV inhibitor RO0730699 in patients... | |||||||||||||
Medical condition: Type 2 diabetes | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: LT (Completed) EE (Completed) LV (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2007-000019-27 | Sponsor Protocol Number: 0431-049 | Start Date*: 2007-03-14 | |||||||||||
Sponsor Name:Merck & Co., Inc | |||||||||||||
Full Title: A Multicenter, Double-Blind, Randomized Study to Evaluate the Safety and Efficacy of Sitagliptin Compared With Metformin in Patients With Type 2 Diabetes Mellitus With Inadequate Glycemic Control | |||||||||||||
Medical condition: type II diabetes mellitus | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: LT (Completed) FI (Completed) IE (Completed) HU (Completed) DK (Completed) ES (Completed) GB (Completed) AT (Completed) GR (Completed) DE (Completed) EE (Completed) BG (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2010-018974-19 | Sponsor Protocol Number: ANA-3786 | Start Date*: 2010-09-03 | |||||||||||
Sponsor Name:Novo Nordisk A/S | |||||||||||||
Full Title: A randomised, controlled, open label, multicentre, multinational, treat-to-target trial investigating the efficacy and safety of intensification with addition of bolus insulin aspart in subjects wi... | |||||||||||||
Medical condition: Type 2 Diabetes | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Completed) SI (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2004-002160-22 | Sponsor Protocol Number: 0431-028 | Start Date*: 2004-11-17 | |||||||||||
Sponsor Name:Merck & Co., Inc. | |||||||||||||
Full Title: A Multicenter, Randomized, Double-Blind Study to Evaluate the Safety of MK-0431 Monotherapy in Patients With Type 2 Diabetes Mellitus and Chronic Renal Insufficiency Who Have Inadequate Glycemic Co... | |||||||||||||
Medical condition: Type 2 Diabetes Mellitus Chronic Renal Insufficiency [MedDRA classification code: 10050441] | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: HU (Completed) ES (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2010-022304-50 | Sponsor Protocol Number: NN1250-3847 | Start Date*: 2011-02-02 | |||||||||||
Sponsor Name:Novo Nordisk A/S | |||||||||||||
Full Title: A trial comparing the efficacy and safety of insulin degludec three times weekly in insulin naïve subjects with type 2 diabetes mellitus when titrated using two different titration algorithms | |||||||||||||
Medical condition: Type 2 Diabetes | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: SK (Completed) HU (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2008-005263-34 | Sponsor Protocol Number: MMB003 | Start Date*: 2009-01-14 | |||||||||||
Sponsor Name:The Mater Foundation/HRB Grant | |||||||||||||
Full Title: The effect of insulin therapy on beta-cell survival in patients with Maturity Onset Diabetes of the Young ( MODY) 3. A 2 year, single-centre, open-label, randomised, parallel-group trial comparing... | |||||||||||||
Medical condition: The effect of insulin therapy on beta-cell survival in patients with Maturity Onset Diabetes of the Young ( MODY ) 3. | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: IE (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2007-001222-27 | Sponsor Protocol Number: EU-IIT-006 | Start Date*: 2007-11-06 | |||||||||||||||||||||
Sponsor Name:Imperial College London | |||||||||||||||||||||||
Full Title: The effect of Pioglitazone on vascular and ventricular function in people with type 2 diabetes PICCOLA | |||||||||||||||||||||||
Medical condition: Diabetes | |||||||||||||||||||||||
|
|||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||
Trial protocol: GB (Completed) | |||||||||||||||||||||||
Trial results: View results |
EudraCT Number: 2009-013289-20 | Sponsor Protocol Number: 1218.61 | Start Date*: 2009-10-22 | ||||||||||||||||
Sponsor Name:Boehringer Ingelheim France | ||||||||||||||||||
Full Title: A Phase III, randomised, double-blind, placebo-controlled parallel group efficacy and safety study of linagliptin 5 mg administered orally once daily over 24 weeks in type 2 diabetic patients with ... | ||||||||||||||||||
Medical condition: Type 2 Diabetes Mellitus | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: FR (Completed) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2018-000359-42 | Sponsor Protocol Number: GOOD-WP2 | Start Date*: 2019-02-18 | ||||||||||||||||
Sponsor Name:FONDAZIONE POLICLINICO UNIVERSITARIO AGOSTINO GEMELLI IRCCS UNIVERSITA' CATTOLICA DEL SACRO CUORE | ||||||||||||||||||
Full Title: Geriatric outcomes among older Type 2 diabetic patients treated with DPP4 inhibitors or glinides: focus on sarcopenia markers of muscle and physical performance status (GOOD-WP2) | ||||||||||||||||||
Medical condition: Elderly patients suffering from type 2 diabetes mellitus in treatment with metformina | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: IT (Completed) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2013-000542-19 | Sponsor Protocol Number: TAK-875_310 | Start Date*: 2013-07-31 | |||||||||||||||||||||||||||||||
Sponsor Name:Takeda Development Centre (Europe) Ltd. | |||||||||||||||||||||||||||||||||
Full Title: A Phase 3, Multicenter, Randomized, Double-Blind, Active-Controlled, 24-Week Study to Evaluate the Efficacy and Safety of Daily Oral TAK-875 50 mg Compared With Sitagliptin 100 mg When Used in Comb... | |||||||||||||||||||||||||||||||||
Medical condition: Type 2 diabetes mellitus (T2DM) | |||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||||||||||||
Trial protocol: HU (Prematurely Ended) HR (Prematurely Ended) | |||||||||||||||||||||||||||||||||
Trial results: View results |
EudraCT Number: 2014-005375-91 | Sponsor Protocol Number: NN9535-4216 | Start Date*: Information not available in EudraCT | |||||||||||
Sponsor Name:Novo Nordisk A/S | |||||||||||||
Full Title: Efficacy and safety of semaglutide versus dulaglutide as add-on to metformin in subjects with type 2 diabetes | |||||||||||||
Medical condition: Diabetes Mellitus, Type 2 | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IE (Completed) FI (Completed) DE (Completed) GB (Completed) SK (Completed) LV (Completed) LT (Completed) GR (Completed) ES (Completed) PT (Completed) HR (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2016-004965-22 | Sponsor Protocol Number: NN9535-4339 | Start Date*: 2017-06-08 | |||||||||||
Sponsor Name:Novo Nordisk A/S | |||||||||||||
Full Title: Efficacy and safety of semaglutide 1.0 mg once-weekly versus liraglutide 1.2 mg once-daily as add-on to 1-3 oral anti-diabetic drugs (OADs) in subjects with type 2 diabetes | |||||||||||||
Medical condition: Diabetes Mellitus, Type 2 | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: SI (Completed) HU (Completed) FR (Completed) FI (Completed) ES (Completed) SE (Completed) BG (Completed) GB (Completed) CZ (Completed) PL (Completed) IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2008-004790-18 | Sponsor Protocol Number: 2008DM05 | Start Date*: 2008-10-21 | |||||||||||
Sponsor Name:University of Dundee | |||||||||||||
Full Title: Response to Oral Agents in Diabetes (ROAD) Pilot Study | |||||||||||||
Medical condition: Type 2 diabetes | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2014-004643-12 | Sponsor Protocol Number: POP6739 | Start Date*: 2015-03-26 | |||||||||||
Sponsor Name:Sanofi-aventis | |||||||||||||
Full Title: Post-marketing study of Amaryl® (Glimepiride) in patients with type 2 diabetes to investigate pediatric and adult population pharmacokinetics [multicenter, non-comparative, 12-28 weeks, non-blind t... | |||||||||||||
Medical condition: Patients with type 2 diabetes | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: Outside EU/EEA | |||||||||||||
Trial results: View results |
EudraCT Number: 2007-000594-29 | Sponsor Protocol Number: PEA001 | Start Date*: 2007-04-25 | |||||||||||
Sponsor Name:NHS Tayside | |||||||||||||
Full Title: The use of glycaemic response to sulphonylureas as a tool to investigate Type 2 diabetes pathophysiology | |||||||||||||
Medical condition: Type 2 diabetes | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Prematurely Ended) | |||||||||||||
Trial results: View results |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
